Showing 6271-6280 of 8826 results for "".
- First Patient Dosed in Phase II Clinical Trial of TLL018-205 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-ii-clinical-trial-of-tll018-205-for-pso/2461511/The first patient has been enrolled and dosed in a Phase II study evaluating the efficacy and safety of TLL-018 fpr moderate to severe plaque psoriasis. This study is sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd (Highlightll Pharmaceutical, USA). T
- Investigational Topical Peptide May Help Tame Eczemahttps://practicaldermatology.com/news/investigational-topical-peptide-may-help-tame-eczema/2461503/A new investigational topical peptide may can block inflammatory signaling in a preclinical model of atopic dermatitis – eczema, researchers at Vanderbilt University Medical Center (VUMC) report. Treatment for severe cases of eczema includes immunosuppressive drugs
- Dr. B Expands Telehealth Service into Dermatologyhttps://practicaldermatology.com/news/dr-b-expands-telehealth-service-into-dermatology/2461498/Telehealth service Dr. B added several specialties to it service network, including dermatology. The move allows patients to access low or no-cost virtual doctor consultations for a variety of conditions from home. Dr. B’s online consultation fee is $15 for paying p
- Can-Fite Submits Market Registration Plan for Psoriasis Treatment Piclidenoson in Europe; FDA Submission to Followhttps://practicaldermatology.com/news/can-fite-submits-market-registration-plan-for-psoriasis-treatment-piclidenoson-in-europe-fda-submission-to-follow/2461494/Can-Fite BioPharma announced it has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson in the treatment of moderate to severe psoriasis. The company said a submission to the FDA will follow. Piclidenoson is a no
- Study Reveals Novel Insights on Melanin Formationhttps://practicaldermatology.com/news/study-reveals-novel-insights-on-melanin-formation/2461491/“Nrf3” regulates the process of melanin production in mouse and human cells, a new study shows. NF-E2-related factor 3 or “Nrf3,” a known transcription factor, or protein involved in the pro
- Can the Sunshine Vitamin Lower Melanoma Risk?https://practicaldermatology.com/news/can-the-sunshine-vitamin-lower-melanoma-risk/2461490/
- Current Depression, Systemic Inflammation Linked in Psoriasishttps://practicaldermatology.com/news/current-depression-systemic-inflammation-linked-in-psoriasis/2461482/Current depression travels with increased neutrophils in psoriasis patients, especially females, finds research in the Journal of Investigative Dermatology. For the study, re
- UCSF Apologizes for Dermatology Experiments in Prisoners in 1960shttps://practicaldermatology.com/news/ucsf-apologizes-for-dermatology-experiments-in-prisoners-in-1960s/2461477/The University of California, San Francisco apologized for conducting unethical dermatology experiments on at least 2,600 incarcerated men in the 1960s and 1970s. Experiments included putting pesticides and herbicides on the men’s skin and injecting it into the
- Endo Removes Qwo from Market Due to Concerns About Injection Site Bruising, Skin Discolorationhttps://practicaldermatology.com/news/endo-removes-qwo-from-market-due-to-concerns-about-injection-site-bruising-skin-discoloration/2461467/Endo International plc is ceasing the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloratio
- New Melanoma Immunotherapy Drugs Are Saving Liveshttps://practicaldermatology.com/news/new-melanoma-immunotherapy-drugs-are-saving-lives/2461462/New research suggest that the use of new pharmacological therapies is associated with a decrease in the melanoma mortality rate in the U.S. population. In the population-based cross-sectional study of patients with cutaneous melanoma from the Surveillance, Epidemiology, and E